About: A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 18 August 2011

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 2011 (uk) article scientifique publié en 2011 (fr) scientific article published on 18 August 2011 (en) artículu científicu espublizáu n'agostu de 2011 (ast)
publication date	wds:Q84787180-9A1F75DF-D627-481B-B47F-069F6652E7D4
publication date	2011-08-18 00:00:00Z (xsd:dateTime)
cites work	wds:Q84787180-69954098-FE0F-400E-9F8B-E4876FEB8D35
cites work	Cancer statistics, 2009
author name string	wds:Q84787180-1A98ACDD-B4C0-4AF1-9968-D63B77BAC299 wds:Q84787180-2D9A85A6-7116-4D9A-8D02-83FFCB418AFF wds:Q84787180-39657CCF-83AA-4E74-8E7F-2FA2350528E6 wds:Q84787180-3F8384FA-E1FC-4A27-9F9D-A1AC407743FB wds:Q84787180-61B98655-23B9-4D60-B543-B374E82FAB0F wds:Q84787180-885B30C0-2BFD-4621-A5E8-C5E9689E0C71 wds:Q84787180-B1901C70-768D-4506-91BD-CB443E16D64D
author name string	David Siegel Julian Adams Emmanuel Normant Jill Goddard David Grayzel Joi Dunbar Ivan Borello
rdfs:label	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma (en) A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma (nl)
skos:prefLabel	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma (en) A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma (nl)
name	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma (en) A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma (nl)
author	wds:Q84787180-16E9F90E-B952-46D4-B2F8-EDD951F2E300 wds:Q84787180-3747374B-9294-49F7-B44F-BB11C8FAB420 wds:Q84787180-44B5896B-31BD-4F2A-9ACE-630F02FB1637 wds:Q84787180-89C989F1-8097-4740-B1A3-05AD791797D5 wds:Q84787180-BBA8DD0D-37F5-4661-841C-457AAF025498 wds:Q84787180-EB0F605A-601D-4D7B-BC7A-793226A1AD2C
author	Kenneth C. Anderson Paul G. Richardson David Vesole Constantine S Mitsiades Sundar Jagannath Amitabha Mazumder
title	wds:Q84787180-8F7B5AEF-5067-4FB4-8F40-DC28BF36F008
title	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma (en)
page(s)	wds:Q84787180-77B01A4E-F0E8-447B-BD8C-A7CDFFA26A03
page(s)	2308-2315
instance of	wds:Q84787180-4943B982-7341-400A-A7B7-E5CB1CB5C5C3
instance of	scholarly article
main subject	wds:Q84787180-61720F70-30B8-43F2-9DC8-98FD9676293E wds:Q84787180-D5CE5E82-1856-4F27-B68D-87034B1A495B
main subject	multiple myeloma retaspimycin hydrochloride
PubMed ID	wds:Q84787180-A3194ACB-BF00-4E15-A7E5-5D3302DAD32B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21851215
PubMed ID	21851215
published in	wds:Q84787180-FAAAE76B-5DA8-4D67-831F-F9B85F18D08C
published in	Leukemia & Lymphoma
issue	wds:Q84787180-96BB6D71-A345-461A-8438-32B8E2F02BEC
volume	wds:Q84787180-2B7F6269-2E27-4C6B-AC25-94A39A65DEF7
issue	12
volume	52
DOI	wds:Q84787180-E42926B4-5640-4AED-9849-1165F3CC2B76
DOI	http://dx.doi.org/10.3109/10428194.2011.600481
DOI	10.3109/10428194.2011.600481
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q84787180
is cites work of	Heat shock proteins in multiple myeloma Inhibition of HSP90 molecular chaperones: moving into the clinic Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer 19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity New strategies in the treatment of multiple myeloma Multiple Myeloma: Treatment is Getting Individualized Heat shock protein 90 (hsp90) expression and breast cancer Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside? A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Model of translational cancer research in multiple myeloma Associating lncRNAs with small molecules via bilevel optimization reveals cancer-related lncRNAs
is cites work of	wds:Q38199919-C32EE2CF-68BF-44D9-B912-6D930073CDFC wds:Q36522964-F7D54372-B826-4386-8C5C-9128305DF1CE wds:Q36498784-A05CFCEF-B1E8-4120-9C9A-16F3DAA96BE3 wds:Q36821702-F824B275-90DA-48C2-A21C-1B6AA99E9681 wds:Q33958520-3C1E81E1-57C7-4300-BF58-50D02655474B wds:Q38502737-48E6FFA5-B0BA-4A17-9074-612C2838ED48 wds:Q34654791-46D43EB2-F976-4168-BAE5-7644E0F8A5D4 wds:Q34164027-FF441C82-A690-4ED9-98A1-08A2E4925762 wds:Q33584583-90B58DE2-CBC7-4187-9E76-A87F0766550D wds:Q47105068-161B758D-F7B6-4FC8-8602-8A76D8DF7E12 wds:Q92251829-FC13D7C8-6331-4473-A43D-A596CFB25FFA wds:Q42922811-AB8A8E2A-D164-4189-A99F-23B112F6DF67

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software